Copyright
©The Author(s) 2020.
World J Clin Cases. Jul 6, 2020; 8(13): 2727-2737
Published online Jul 6, 2020. doi: 10.12998/wjcc.v8.i13.2727
Published online Jul 6, 2020. doi: 10.12998/wjcc.v8.i13.2727
Table 1 Comparison of clinical characteristics, laboratory findings, pulmonary function test, and inhaled medications between EOS group and non-EOS group
Variables | EOS group (n = 176) | Non-EOS group (n = 449) | P value |
Male (%) | 166 (94.3) | 384 (85.5) | 0.004 |
BMI | 23.52 ± 4.19 | 23.23 ± 4.23 | 0.441 |
Age, yr | 74.90 ± 11.74 | 76.89 ± 10.09 | 0.049 |
Smoking, n (%) | 0.054 | ||
Never | 45 (25.6) | 142 (31.6) | |
Current | 54 (30.7) | 98 (21.8) | |
Ex-smoker | 77 (43.8) | 209 (46.5) | |
Hemogram values | |||
Leukocyte count, 109/ L | 8723.92 ± 3447.99 | 11002.72 ± 4311.44 | 0.000 |
Neutrophil, % | 64.50 ± 9.89 | 77.74 ± 9.86 | 0.000 |
Monocyte, % | 6.96 ± 2.20 | 6.71 ± 3.05 | 0.253 |
Lymphocyte, % | 21.30 ± 8.18 | 13.13 ± 8.50 | 0.000 |
Eosinophil count, % | 6.47 ± 3.81 | 0.79 ± 0.84 | 0.000 |
Basophil, % | 0.40 ± 0.30 | 0.19 ± 0.28 | 0.000 |
Hemoglobin, g/dL | 13.25 ± 2.31 | 13.24 ± 2.11 | 0.942 |
Hematocrit, % | 39.31 ± 6.33 | 39.37 ± 5.83 | 0.909 |
MCV, fL | 88.58 ± 7.58 | 89.35 ± 6.99 | 0.228 |
Platelet count, 103/µL | 228.14 ± 86.15 | 206.59 ± 70.09 | 0.001 |
Mean platelet volume, fL | 9.63 ± 0.76 | 9.75 ± 0.81 | 0.106 |
Neutrophil count, 109/L | 5715.46 ± 2872.96 | 8718.93 ± 3962.78 | 0.000 |
Lymphocyte count, 109/ L | 1770.57 ± 822.48 | 1294.99 ± 840.47 | 0.000 |
Eosinophil count, 109/ L | 543.18 ± 351.54 | 76.16 ± 82.77 | 0.000 |
Neutrophil-to-lymphocyte ratio | 4.39 ± 6.29 | 10.59 ± 13.11 | 0.000 |
Infection status, n (%) | |||
CXR infiltrate | 18 (10.2) | 83 (18.5) | 0.016 |
Fever | 9 (5.1) | 51 (11.4) | 0.026 |
Antibiotics | 145 (82.4) | 404 (90.0) | 0.013 |
Inflammatory markers | |||
CRP | 2.08 ± 3.76 | 4.64 ± 5.75 | 0.000 |
Home noninvasive ventilation, n (%) | 18 (10.2) | 43 (9.6) | 0.923 |
Comorbidities, n (%) | |||
Neuromuscular disease | 25 (14.2) | 32 (7.1) | 0.009 |
Ischemic heart disease | 35 (19.9) | 92 (20.5) | 0.954 |
Cancer | 8.0 (14) | 30 (6.7) | 0.705 |
ESRD | 0 (0) | 3 (0.6) | 0.370 |
Hypertension | 82 (46.6) | 208 (46.3) | 0.715 |
Diabetes mellitus | 28 (15.9) | 65 (14.5) | 0.743 |
Liver cirrhosis | 3 (1.7) | 3 (0.6) | 0.238 |
Autoimmune disease | 1 (0.6) | 9 (2.0) | 0.327 |
Pulmonary function tests | |||
FVC (L) | 2.14 ± 0.77 | 1.94 ± 0.65 | 0.002 |
FVC % predicted | 75.66 ± 27.52 | 73.16 ± 22.76 | 0.285 |
FEV1(L) | 1.07 ± 0.43 | 1.02 ± 0.42 | 0.247 |
FEV1 % predicted | 47.20 ± 17.70 | 48.55 ± 17.69 | 0.393 |
FEV1/FVC % | 50.90 ± 12.70 | 53.12 ± 13.02 | 0.054 |
Bronchodilator response, n (%) | 80 (45.5) | 170 (37.9) | 0.099 |
Inhaled medications before admission, n (%) | |||
LAMA | 13 (7.4) | 32 (7.1) | 0.910 |
LAMA + LABA | 4 (2.3) | 13 (2.9) | 0.667 |
ICS + LABA | 43 (24.4) | 112 (24.9) | 0.894 |
LAMA + LABA + ICS | 68 (38.6) | 155 (34.5) | 0.334 |
- Citation: Wu CW, Lan CC, Hsieh PC, Tzeng IS, Wu YK. Role of peripheral eosinophilia in acute exacerbation of chronic obstructive pulmonary disease. World J Clin Cases 2020; 8(13): 2727-2737
- URL: https://www.wjgnet.com/2307-8960/full/v8/i13/2727.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v8.i13.2727